Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Acemet, Acemetacin intermuti, Flamarion, Tendonil, Pranex, Mocetasin,Rheutrop
Synonyms :
acemetacin
Class :
Non-steroidal anti-inflammatory drug, Analgesic, Non-opioid
Brand Name :
Acemet, Acemetacin intermuti, Flamarion, Tendonil, Pranex, Mocetasin,Rheutrop
Synonyms :
acemetacin
Class :
Non-steroidal anti-inflammatory drug, Analgesic, Non-opioid
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may have a decrease in excretion rate when combined with tetradecyl sulfuric acid
acemetacin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
NSAIDs may increase the serum concentration of Lithium
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of hypertension when combined
may diminish the excretion rate of amantadine
may have an increased hyperkalemia when combined with acemetacin
may enhance the risk of hyperglycemia when combined
may increase the risk of adverse effects when combined
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
it increases the toxicity of NSAIDs
it increases the toxicity of NSAIDs
it increases the toxicity of NSAIDs
it increases the toxicity of NSAIDs
it increases the toxicity of NSAIDs
When suprofen is taken in conjunction with acemetacin, there is a potential for an enhance in the seriousness of adverse events
it decreases the rate of elimination of pidotimod
Ketorolac may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents
neuroexcitatory actions of cinoxacin can increase with acemetacin
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
acemetacin may increase the serum concentration of penicillins
acemetacin may increase the serum concentration of penicillins
acemetacin may increase the serum concentration of penicillins
acemetacin may increase the serum concentration of penicillins
acemetacin may increase the serum concentration of penicillins
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
acemetacin: they may enhance the serum concentration of penicillins
amoxicillin and clavulanate potassium
acemetacin: they may enhance the serum concentration of penicillins
acemetacin: they may enhance the serum concentration of penicillins
acemetacin: they may enhance the serum concentration of penicillins
acemetacin: they may enhance the serum concentration of penicillins
By competing with acidic (anionic) drugs for renal clearance, acemetacin will raise the amount of probenecid
may increase the anticoagulation ginkgo biloba
The combination of antipyrine with acemetacin may elevate the seriousness of adverse events
The seriousness of nephrotoxic effect is enhanced when acecmetacin is used in conjunction with cefotiam
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
When aminophenazone is taken together with acemetacin, there is a potential for an elevated risk or enhanced seriousness of adverse events
acemetacin Might lead to a reduction in the rate of excretion of triethylenetetramine, potentially leading to elevated levels of serum
Combining xamoterol with acemetacin may elevate the risk/seriousness of hypertension
levobetaxolol's antihypertensive properties might be reduced by acemetacin
It may enhance the risk of bleeding when combined with nimesulide
acemetacin has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
It may enhance the risk of adverse effects when combined with Glycopeptides
It may enhance the risk of adverse effects when combined with Glycopeptides
When loracarbef is used together with acemetacin, the risk or seriousness of nephrotoxicity is enhanced
When acemetacin is used together with hexoprenaline, the potential for hypertension to occur may be elevated
When acemetacin is used together with sertraline, the risk or seriousness of bleeding may be enhanced
When acemetacin is used together with piroxicam, this leads to enhanced risk or seriousness of adverse outcomes
When antrafenine is used together with acemetacin, this leads to enhanced risk or seriousness of adverse outcomes
When acemetacin is used together with cephaloglycin, this leads to increased risk or seriousness of nephrotoxicity
When melitracen is used together with acemetacin, this leads to increased risk or seriousness of gastrointestinal bleeding
When acemetacin is used together with abediterol, this leads to enhanced risk or seriousness of hypertension
When andrographolide is used together with acemetacin, this leads to enhanced risk or seriousness of bleeding
When acemetacin is used together with proglumetacin, this leads to enhanced risk or seriousness of adverse events.
When acemetacin is used together with bufexamac, this leads to enhanced risk or seriousness of adverse events
flupirtine excretion rate may be slowed by acemetacin, raising the possibility of higher serum levels
When acemetacin is used together with benoxaprofen, this leads to enhanced risk or seriousness of adverse events
acemetacin leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
acemetacin leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
acemetacin leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
acemetacin leads to a reduction in the rate of excretion of oxyquinoline, which leads to an increased level of serum
the risk or severity of adverse effects may increase when acemetacin is combined with alendronic acid
acemetacin leads to a reduction in the rate of excretion of estrone sulfate, which leads to an increased level of serum
When lopinavir is used together with acemetacin, this leads to enhanced risk or seriousness of nephrotoxicity
the severity or risk of hypertension can increase when dihydroergocristine is combined with acemetacin
gadopentetic acid may decrease the excretion rate of acemetacin, potentially leading to a higher serum level
the excretion rate of ioxilan may be decreased by acemetacin, potentially resulting in a higher serum level
acemetacin leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
combining isoxicam with acemetacin may increase the risk or severity of adverse effects
phylloquinone may decrease the excretion rate of acemetacin, potentially leading to higher serum levels
the therapeutic efficacy of muzolimine may be diminished when used concurrently with acemetacin
acemetacin may reduce the excretion rate of mycophenolic acid, leading to a potential increase in serum levels
the excretion rate of n-acetyl tyrosine may be decreased by acemetacin, potentially leading to higher serum levels
the excretion rate of sulbactam may be decreased by acemetacin, potentially leading to higher serum levels
acemetacin: it may decrease the excretion rate of iothalamic acid
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
acemetacin: it may decrease the excretion rate of abacavir CNS depressant
When acemetacin is used together with nifenazone, this leads to enhanced risk or seriousness of adverse events
sulfinpyrazone may lower the excretion rate of acemetacin, potentially resulting in a raised serum level
acemetacin: it may decrease the antihypertensive activities of oxprenolol
acemetacin: it may increase the risk of adverse effects with indobufen
acemetacin and clonixin used together may increase the likelihood or extent of side effects
the risk or extent of adverse effects can be increased when flunixin is combined with acemetacin
acemetacin: it may enhance the toxic effect of Anti-Inflammatory Agents
acemetacin: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
acemetacin: it may enhance the toxic effect of Anti-Inflammatory Agents
acemetacin: it may enhance the toxic effect of Anti-Inflammatory Agents
acemetacin: it may enhance the toxic effect of Anti-Inflammatory Agents
the risk or extent of adverse effects can be increased when niflumic acid is combined with acemetacin
when isometheptene is coupled with acemetacin, the risk or degree of BP may increase
acemetacin may diminish the excretion speed of hydroxyethyl starch, potentially leading to an elevated serum level
choline magnesium trisalicylateÂ
the hazard or intensity of adverse effects can be heightened when Choline magnesium trisalicylate is combined with acemetacin
acemetacin: it may decrease the therapeutic efficacy of phentolamine
When acemetacin is used together with diazoxide, this leads to reduction in therapeutic effectiveness of diazoxide
Therapy monitoring suggested. May increase serum concentrations when interacting with penicillins.
The interaction may increase the serum concentration of cloxacillin and lead to allergic reactions.
Decrease the excretion rate of azlocillin which could result in a higher serum level of the drug.
it enhances the serum potassium levels
it may enhance the serum potassium levels
may increase the risk or severity of hypertension when combined
may enhance the risk or severity of hypertension when combined
may decrease the tiopronin excretion rate
may increase the risk or severity of hypertension when combined
anticoagulation is increased by acemetacin and decreased by mistletoe. The interaction's effect is unclear; exercise caution
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the anticoagulation effect when combined
the excretion rate of ribostamycin is reduced by acemetacin, which results in higher serum concentration
an increase in the risk of adverse effects can be seen when mofebutazone is taken with acemetacin
the rate of excretion of benzylpenicilloyl polylysine may be reduced with acemetacin
the rate of excretion of inositol may be reduced
the risk of adverse effects may be increased
the hyperkalemic activity of acemetacin may be increased
the risk of side effects can be raised when sulindac is used in combination
when acemetacin is combined with prenylamine, there is an increased risk or severity of hyperkalemia
the risk of gastrointestinal bleeding may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of hypertension may be increased
the therapeutic effect of Remikiren may be reduced
the therapeutic activity of candoxatril may be reduced
the risk of adverse effects may be increased
the risk of hypertension, renal failure, and hypokalemia may be increased
the risk of hypertension may be increased
acemetacin may reduce the excretion rate of inosine pranobex, potentially causing a higher serum level
the risk or intensity of gastrointestinal bleeding can be heightened when acemetacin is combined with ibandronate
both forskolin and acemetacin enhance anticoagulation
acemetacin might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Increased serum concentration level by competitive plasma protein binding.
when both drugs are combined, there may be an increased effect of acemetacin by acidic (anionic) drug competition for renal tubular clearance 
may enhance the effect of the other by cationic drug competition for renal tubular clearance
Actions and Spectrum:Â
The mechanism of action of acemetacin is similar to that of other NSAIDs. It works by inhibiting the activity of cyclooxygenase (COX) enzymes, which are responsible for synthesizing prostaglandins, prostacyclin, and thromboxane. Prostaglandins are important mediators of pain, inflammation, and fever, and their inhibition reduces these symptoms. Â
acemetacin is more selective for COX-2 than COX-1, which means it has a lower risk of causing gastrointestinal side effects than other NSAIDs. However, it can still cause side effects such as stomach ulcers, bleeding, and kidney problems, mainly when used for long periods or at high doses. Â
acemetacin has a broad spectrum of activity and can treat various conditions, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, and menstrual pain. It is also used to reduce fever and relieve pain caused by other conditions, such as headache and dental pain.Â
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: acemetacin should not be used during pregnancy.Â
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
acemetacin is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with various conditions such as osteoarthritis and rheumatoid arthritis. Â
acemetacin works by inhibiting the production of prostaglandins, substances in the body that cause pain, inflammation, and fever. Specifically, acemetacin inhibits the activity of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are involved in the production of prostaglandins.Â
Pharmacodynamics:Â
The pharmacodynamics of acemetacin involve its interaction with cyclooxygenase enzymes (COX-1 and COX-2), which are involved in the production of prostaglandins, substances that play a role in inflammation and pain. Â
acemetacin is a prodrug metabolized in the body into its active form, indomethacin. Indometacin is a non-selective inhibitor of both COX-1 and COX-2 enzymes, which results in the inhibition of prostaglandin synthesis. This leads to the reduction of pain, inflammation, and fever. Â
Inhibition of COX-1 by acemetacin can lead to gastrointestinal side effects. COX-1 is essential for maintaining the integrity of the gastrointestinal tract, so its inhibition can cause damage to the lining of the intestines and stomach Â
Inhibition of COX-2 by acemetacin can also lead to side effects such as renal toxicity and cardiovascular events. COX-2 is involved in the synthesis of prostaglandins, which modulate blood flow to the kidneys and preserve renal function. Inhibition of COX-2 can therefore reduce blood flow to the kidneys and impair their function. COX-2 also produces prostaglandins that regulate blood flow to the heart and protect against thrombosis. Â
Pharmacokinetics:Â
AbsorptionÂ
acemetacin is rapidly and almost completely absorbed after oral administration. It is well absorbed from the small intestine, and its bioavailability is approximately 90%.  Â
DistributionÂ
acemetacin is highly protein-bound (more than 99%) to albumin. It has a relatively large distribution volume, indicating that it is widely distributed in the body. acemetacin crosses the blood-brain barrier and the placenta, and it is also present in breast milk. Â
MetabolismÂ
acemetacin undergoes extensive metabolism in the liver. It is metabolized to its active metabolite, indometacin, also an NSAID. The metabolism of acemetacin is mediated by cytochrome P450 enzymes, mainly CYP2C9 and CYP3A4. Â
Elimination and ExcretionÂ
acemetacin and its metabolites are primarily excreted in the urine. The elimination half-life of acemetacin is approximately 4-5 hours. The renal clearance of acemetacin is approximately 70% of the total clearance.Â
Administration:Â
acemetacin is usually administered orally in the form of capsules or tablets. Â
Taking acemetacin with food or immediately after a meal is recommended to reduce the risk of gastrointestinal side effects.
Patient information leafletÂ
Generic Name: acemetacinÂ
Why do we use acemetacin?Â
acemetacin is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by a variety of conditions, including:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
